clinical development raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
In May 2025, the Italian Ministry of Health ordered the retail chain ODStore to recall Java Monster Vanilla and Java Monster Mocha, because their caffeine content (300 mg per can) was not in compliance with the legal limits.
As leader of the US delegation, Secretary of State Clinton lauded India as "an indispensable partner and a trusted friend". President Obama appeared briefly at a United States Department of State reception to declare his firm belief that America's relationship with India "will be one of the defining partnerships of the 21st century." The Strategic Dialogue produced a joint statement in which the two countries pledged to "deepen people-to-people, business-to-business, and government-to-government linkages ... for the mutual benefit of both countries and for the promotion of global peace, stability, economic growth and prosperity." It outlined extensive bilateral initiatives in ten key areas: (1) advancing global security and countering terrorism, (2) disarmament and nonproliferation, (3) trade and economic relations, (4) high technology, (5) energy security, clean energy, and climate change, (6) agriculture, (7) education, (8) health, (9) science and technology, and (10) development. In November 2010, Obama became the second US president (after Richard Nixon in 1969) to undertake a visit to India in his first term in office. On 8 November, Obama also became the second US president (after Dwight D. Eisenhower in 1959) to ever address a joint session of the Parliament of India. In a major policy shift, Obama declared US support for India's permanent membership on the UN Security Council. Calling the India–U.S.
Female puberty generally occurs between the ages of 9 and 13 and is characterized by ovulation and menstruation; the growth of secondary sex characteristics, such as growth of pubic and underarm hair, breast, uterine and vaginal growth, widening hips and increased height and weight, also occur during puberty. Male puberty sees the further development of the human penis and testicles. The female inner sex organs are the two ovaries, their fallopian tubes, the uterus, and the cervix. At birth there are about 70,000 immature egg cells that degenerate until at puberty there are around 40,000. No more egg cells are produced. Hormones stimulate the beginning of menstruation, and the ongoing menstrual cycles. The female external sex organs are the vulva (labia, clitoris, and vestibule). The male external genitalia include the penis and scrotum that contains the testicles. The testicles are gonads that produce the sperm cells which are ejaculated in semen through the penis. Unlike the egg cells in the female, sperm cells are produced throughout life. Other internal sex organs are the epididymides, vasa deferentia, and some accessory glands. Diseases that affect the reproductive system include polycystic ovary syndrome, a number of disorders of the testicles including testicular torsion, and a number of sexually transmitted infections including syphilis, HIV, chlamydia, HPV and genital warts. Cancer can affect most parts of the reproductive system including the penis, testicles, prostate, ovaries, cervix, vagina, fallopian, uterus and vulva.
==== Other drugs ==== Alpiropride (Revistel, Rivistel, Rivestel) – dopamine D2 receptor antagonist – migraine Dimetotiazine (Banistyl, Normelin) – non-selective monoamine receptor modulator – migraine Flumedroxone acetate (Demigran, Leomigran) – progestogen (progesterone receptor agonist) – migraine Iprazochrome (Divascan) – serotonin receptor antagonist – migraine Lasmiditan (COL-144; LY-573144; Rayvow; Reyvow) – serotonin 5-HT1F receptor agonist – migraine [141] Lomerizine (DE-090; KB-2796; Migsis) – non-selective monoamine receptor modulator, other actions – migraine [142] Onabotulinum toxin A (BoNTA; Botox; GSK-1358820; OnabotA X; Vistabel; Vistabex) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [143] Oxetorone (Nocertone, Oxedix) – non-selective monoamine receptor modulator – migraine Topiramate (Epitomax; KW-6485; MCN-4853; RWJ-17021; Topamax; Topimax; Topina) – various actions – migraine [144] Topiramate oral (Eprontia; ET-101) – various actions – migraine [145] Topiramate extended-release (SPN-538; TPM XR; Trokendi XR; Trokesa) – various actions – migraine [146] Valproate semisodium (Depakote; Divalproex; Divalproex sodium; Epival; LA40220) – various actions – migraine [147]
==== Binding RuBP ==== Carbamylation of the ε-amino group of Lys210 is stabilized by coordination with the Mg2+. This reaction involves binding of the carboxylate termini of Asp203 and Glu204 to the Mg2+ ion. The substrate RuBP binds Mg2+ displacing two of the three aquo ligands.
Sources: en.wikipedia.org
== Biochemical mechanism and function of transamination == Transamination is responsible for the deamination of most amino acids, and one of the major degradation pathways which convert essential amino acids to non-essential amino acids (amino acids that can be synthesized de novo by the organism).
The influence of Nasser's Arab nationalism over the RCC was immediately apparent. The administration was instantly recognized by the neighbouring Arab nationalist regimes in Egypt, Syria, Iraq, and Sudan, with Egypt sending experts to aid the inexperienced RCC. Gaddafi propounded pan-Arab ideas, proclaiming the need for a single Arab state stretching across North Africa and the Middle East. In December 1969, Libya signed the Tripoli Charter alongside Egypt and Sudan. This established the Arab Revolutionary Front, a pan-national union designed as a first step towards the eventual political unification of the three nations. In 1970 Syria declared its intention to join. Nasser died unexpectedly in September 1970, with Gaddafi playing a prominent role at his funeral. Nasser was succeeded by Anwar Sadat, who replaced the idea of a unified state with a political federation, implemented in April 1971; in doing so, Egypt, Syria, and Sudan received large grants of Libyan oil money. In July 1971, Gaddafi sided with Sadat against the Soviet Union in the 1971 Sudanese coup d'état and dispatched Libyan fighter jets to force down a British Overseas Airways Corporation jetliner carrying the leading coup plotters, Farouk Osman Hamadallah and Babikir al-Nour. They were extradited back to Khartoum, where they were promptly executed by Sudanese leader Jaafar Nimeiry. In February 1972, Gaddafi and Sadat signed an unofficial charter of merger, but it was never implemented because relations broke down the next year.
=== Mechanical ventilation === Isolated mechanical forces may not adequately explain ventilator induced lung injury (VILI). The damage is affected by the interaction of these forces and the pre-existing state of the lung tissues, and dynamic changes in alveolar structure may be involved. Factors such as plateau pressure and positive end-expiratory pressure (PEEP) alone do not adequately predict injury. Cyclic deformation of lung tissue may play a large part in the cause of VILI, and contributory factors probably include tidal volume, positive end-expiratory pressure and respiratory rate. There is no protocol guaranteed to avoid all risk in all applications.
== Side effects == The most common side effects in studies were decreased blood cell counts, mainly neutropenia (in 75% of patients, as compared to 5% under placebo), but also anemia (18% vs. 5%). Gastrointestinal disorders were also common, for example nausea (52% vs. 29%) and diarrhea (35% vs. 22%), as was alopecia (33% vs. 16%). The drug also increases the QT interval and liver enzymes (alanine transaminase, aspartate transaminase). The most common side effects include infections, low levels of white blood cells, headache, cough, nausea, vomiting, diarrhoea, constipation, tiredness, hair loss and rash. The most common severe side effects include infections, low levels of red and white blood cells, vomiting, abnormal blood tests for liver function and low levels of phosphate in the blood (hypophosphataemia).
As noted above, in radioactive decay the half-life is the length of time after which there is a 50% chance that an atom will have undergone nuclear decay. It varies depending on the atom type and isotope, and is usually determined experimentally. See List of nuclides. The current flowing through an RC circuit or RL circuit decays with a half-life of ln(2)RC or ln(2)L/R, respectively. For this example the term half time tends to be used rather than "half-life", but they mean the same thing. In a chemical reaction, the half-life of a species is the time it takes for the concentration of that substance to fall to half of its initial value. In a first-order reaction the half-life of the reactant is ln(2)/λ, where λ (also denoted as k) is the reaction rate constant.
Sources: en.wikipedia.org
According to the first option, the spent nuclear fuel is considered complete waste. After an interim storage (wet and dry), all the used fuel is directly disposed of in a deep geological repository. Several geological media and repository designs are being studied according to different natures of fuel and their burnup, radioactive inventory and decay heat generation. The assessment of a geological disposal is based on the multi-barrier approach, which combines multiple effects of engineered and natural barriers in order to delay potential long-lived radionuclide migrations to the biosphere over time. Reprocessing is the alternative option for the spent fuel after a long interim storage. The used fuel is not considered waste anymore but a future energy resource. A large amount of fertile uranium (
=== Second stranding === Between January 9 and January 15, a storm tide dragged the carcass out to sea, but it washed ashore again on the next tide, on Crescent Beach, two miles to the south of its original location. Webb sent photographs of the mass, along with a description, to Joel Asaph Allen of the Museum of Comparative Zoology at Harvard. Allen apparently did not respond, but Webb's letter came to the attention of Prof. Addison Emery Verrill of Yale, at that time the foremost authority on cephalopods in the country. At first, Verrill suggested the carcass might represent the remains of a giant squid. In the January 1897 issue of the American Journal of Science he wrote:
=== 2014 === On January 22, 2014, European Southern Observatory became the first scientific organization to deliver Ultra HD footage at regular intervals. On May 6, 2014, France announced DVB-T2 tests in Paris for Ultra HD HEVC broadcast with objectives to replace by 2020 the current DVB-T MPEG4 HD national broadcast. On May 26, 2014, satellite operator Eutelsat announced the launch of Europe's first Ultra HD demo channel in HEVC, broadcasting at 50 fps. The channel is available on the Hot Bird satellites and can be watched by viewers with 4K TVs equipped with DVB-S2 demodulators and HEVC decoders. In June 2014, the FIFA World Cup of that year (held in Brazil) became the first shot entirely in 4K Ultra HD, by Sony. The European Broadcasting Union (EBU) broadcast matches of the FIFA World Cup to audiences in North America, Latin America, Europe and Asia in Ultra HD via SES' NSS-7 and SES-6 satellites. Indian satellite TV provider unveils its plan to launch 4K UHD service early in 2015 and showcased live FIFA World Cup quarter final match in 4K UHD through Sony Entertainment Television Sony SIX. On June 24, 2014, the CEA updated the guidelines for Ultra High-Definition and released guidelines for Connected Ultra High-Definition, adding support for internet video delivered with HEVC. The CEA is developing a UHD logo for voluntary use by companies that make products that meet CEA guidelines. The CEA also clarified that "Ultra High-Definition", "Ultra HD", or "UHD" can be used with other modifiers and gave an example with "Ultra High-Definition TV 4K".
=== Rotation of sites === The infusion set is replaced regularly, usually every 2–3 days. Insulin absorption becomes less effective the longer the set is left in place, leading to poorer control of blood glucose. For this reason, the site of the infusion set is moved when the set is changed. Often a number of favorite sites for the infusion set are used on a rotation basis.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.